Essais liés11clinical trials
VilleColorado Springslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03832998

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Lasmiditan Migraine Phase 3 NCT04396236 PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine TERMINATED
Donanemab Alzheimer Phase 3 NCT04437511 A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) ACTIVE_NOT_RECRUITING
Atogepant Migraine Phase 3 NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine COMPLETED
Atogepant Migraine Phase 3 NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine COMPLETED
Erenumab Dose 1 Migraine Phase 3 NCT03832998 OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine COMPLETED
sumatriptan nasal powder Migraine Phase 3 NCT03338920 Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents TERMINATED
Pozelimab + Cemdisiran Myasthénie Phase 3 NCT05070858 NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Erenumab Dose 1 Migraine Phase 3 NCT03836040 OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine ACTIVE_NOT_RECRUITING
Rimegepant Migraine Phase 3 NCT05156398 Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects RECRUITING
RAP-219 Épilepsie Phase 3 NCT07594119 FOCUS 2 — Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures RECRUITING
PIPE-307 Dose A SEP Phase 2 NCT06083753 VISTA — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis COMPLETED